Evidence map›Paper›PMID 39945753›Full record

ArticleEmerging microbes & infections2025

Longitudinal seroprevalence of Crimean-Congo hemorrhagic fever virus in Southern Uganda.

Evan A Mihalakakos, Victor Ssempijja, Ruy M Ribeiro, Carmen Molina-Paris, Gerald Katushabe, Josephine Nalwadda, Jonah Omooja, Denis K Byarugaba, Kyle Rosenke, Steven J Reynolds and 5 more

Abstract read
In one paragraph

Article in Emerging microbes & infections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Evan A MihalakakosLaboratory of Virology, Rocky Mountain Laboratories, NIAID/NIH, Hamilton, MT, USA.
Victor SsempijjaLaboratory of Immunoregulation, NIAID/NIH, Bethesda, MD, USA.
Ruy M RibeiroTheoretical Biology and Biophysics Group, Theoretical Division, Los Alamos National Laboratory, Los Alamos, NM, USA.
Carmen Molina-ParisTheoretical Biology and Biophysics Group, Theoretical Division, Los Alamos National Laboratory, Los Alamos, NM, USA.
Gerald KatushabeLaboratory of Virology, NIAID/NIH International Centers for Excellence in Research, UVRI, Entebbe, Uganda.
Josephine NalwaddaLaboratory of Virology, NIAID/NIH International Centers for Excellence in Research, UVRI, Entebbe, Uganda.
Jonah OmoojaLaboratory of Virology, NIAID/NIH International Centers for Excellence in Research, UVRI, Entebbe, Uganda.
Denis K ByarugabaLaboratory of Virology, NIAID/NIH International Centers for Excellence in Research, UVRI, Entebbe, Uganda.
Kyle RosenkeLaboratory of Virology, Rocky Mountain Laboratories, NIAID/NIH, Hamilton, MT, USA.
Steven J ReynoldsLaboratory of Immunoregulation, NIAID/NIH, Bethesda, MD, USA.
Mary K GrabowskiDepartment of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Ronald M GaliwangoRakai Health Sciences Program, Kalisizo, Uganda.
Robert SsekubuguRakai Health Sciences Program, Kalisizo, Uganda.
Heinz FeldmannLaboratory of Virology, Rocky Mountain Laboratories, NIAID/NIH, Hamilton, MT, USA.ORCID 0000-0001-9448-8227
David W HawmanLaboratory of Virology, Rocky Mountain Laboratories, NIAID/NIH, Hamilton, MT, USA.

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
International Center for Excellence in Research (ICER) in Uganda: Impact of ARVsZIAAI001040 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REYNOLDS, STEVEN · 2009 to 2025
$23.5M
Circumcision: HIV/STIs and behaviors in a RCT and post-RCT surveillance; RakaiU01AI075115 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GRAY, RONALD H · 2007 to 2011
$9.3M
Epidemiology and Impact of the HIV, NCD, and Urbanization Syndemic in AfricaR01HL152813 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI CHANG, LARRY WILLIAM · 2021 to 2025
$7.8M
Structural and Social Transitions Among Adolescents in Rakai (SSTAR)R01HD091003 · NICHD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SANTELLI, JOHN S. · 2017 to 2021
$3.7M
The role of penile bacteria and inflammation in HIV susceptibility; Rakai, UgandaR01AI123002 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI LIU, CINDY · 2016 to 2020
$3.3M
Enhanced Provision of Male Circumcision for HIV Prevention, Rakai, UgandaU01AI100031 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GRAY, RONALD H · 2012 to 2014
$3.2M
Neurologic Sequelae of HIV Subtype A and D Infection and ART Rakai UgandaR01MH099733 · NIMH · JOHNS HOPKINS UNIVERSITY · PI SACKTOR, NED C, WAWER, MARIA J · 2013 to 2017
$3.0M
Evaluating Demand Generation (Stylish Man) for HIV/Family Planning Services RakaiR01AI114438 · NIAID · JOHNS HOPKINS UNIVERSITY · PI WAWER, MARIA J · 2014 to 2017
$3.0M
RCT to reduce HIV acquisition and viral load among migrants, Rakai, UgandaR01MH115799 · NIMH · JOHNS HOPKINS UNIVERSITY · PI CHANG, LARRY WILLIAM, WAWER, MARIA J · 2018 to 2022
$2.9M
CHWs, mHealth, and Combination HIV Prevention in a Hotspot: A Randomized TrialR01MH107275 · NIMH · JOHNS HOPKINS UNIVERSITY · PI CHANG, LARRY WILLIAM · 2015 to 2019
$2.7M
Long-term impact of universal treatment and dolutegravir on population HIV virologic and incidence outcomes in Africa: The LONGVIEW StudyR01AI155080 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GRABOWSKI, MARY KATHRYN · 2021 to 2024
$2.5M
Intramural NIH HHS ZIA AI001040NHLBI NIH HHS R01 HL152813NIAAA NIH HHS K01 AA024068NIAID NIH HHS K01 AI125086NIAID NIH HHS K25 AI114461NIAID NIH HHS P30 AI094189NIAID NIH HHS R01 AI114438NIAID NIH HHS R01 AI123002NIAID NIH HHS R01 AI143333NIAID NIH HHS R01 AI155080NIAID NIH HHS R01 AI167048NIAID NIH HHS R21 AI145682NIAID NIH HHS U01 AI075115NIAID NIH HHS U01 AI100031NICHD NIH HHS R01 HD070769NICHD NIH HHS R01 HD091003NIMH NIH HHS F31 MH095649NIMH NIH HHS R01 MH099733NIMH NIH HHS R01 MH105313NIMH NIH HHS R01 MH107275NIMH NIH HHS R01 MH115799
6 · The paper itself

Abstract

Crimean-Congo hemorrhagic fever (CCHF) is a tick-borne disease endemic to many regions of Africa, the Middle East, Southeast Asia and the Balkans. Caused by the CCHF virus (CCHFV), CCHF has been a recognized cause of illness in Uganda since the 1950s and recently, more intensive surveillance suggests CCHFV is widely endemic within the country. Most surveillance has been focused on the Ugandan cattle corridor due to the risk of CCHFV exposure associated with livestock practices. Here we evaluated the seroprevalence of CCHFV in several Southern Ugandan communities outside the cattle corridor combined with longitudinal sample sets to measure the immune response to CCHFV for up to a decade. Interestingly, across three community types, agrarian, trading and fishing, we detected CCHFV seroprevalence in all three but found the highest seroprevalence in fishing communities. We also measured consistent CCHFV-specific antibody responses for up to a decade. Our findings support the conclusion that CCHFV is widely endemic in Uganda and highlight that additional communities may be at risk for CCHFV exposure.

Indexed as

Antibodies, ViralHemorrhagic Fever, CrimeanHemorrhagic Fever Virus, Crimean-CongoAdolescentAdultAnimalsCattleFemaleHumansLongitudinal StudiesMaleMiddle AgedSeroepidemiologic StudiesUgandaYoung AdultAntibodies, ViralAfricaantibodiesCCHFseroprevalenceUganda

Identifiers

PMID39945753
PMCPMC11878160

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.